These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 31914898)

  • 21. Designed Ankyrin Repeat Proteins: A Look at their Evolving Use in Medicine with a Focus on the Treatment of Chorioretinal Vascular Disorders.
    Smithwick E; Stewart MW
    Antiinflamm Antiallergy Agents Med Chem; 2017; 16(1):33-45. PubMed ID: 28464780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Harnessing the power of an expanded genetic code toward next-generation biopharmaceuticals.
    Kang M; Lu Y; Chen S; Tian F
    Curr Opin Chem Biol; 2018 Oct; 46():123-129. PubMed ID: 30059835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro-engineered non-antibody protein therapeutics.
    Simeon R; Chen Z
    Protein Cell; 2018 Jan; 9(1):3-14. PubMed ID: 28271446
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs.
    Jost C; Plückthun A
    Curr Opin Struct Biol; 2014 Aug; 27():102-12. PubMed ID: 25033247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Designed ankyrin repeat proteins as anti-idiotypic-binding molecules.
    Vogel M; Keller-Gautschi E; Baumann MJ; Amstutz P; Ruf C; Kricek F; Stadler BM
    Ann N Y Acad Sci; 2007 Aug; 1109():9-18. PubMed ID: 17785285
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anticalins small engineered binding proteins based on the lipocalin scaffold.
    Gebauer M; Skerra A
    Methods Enzymol; 2012; 503():157-88. PubMed ID: 22230569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage.
    Eggel A; Baumann MJ; Amstutz P; Stadler BM; Vogel M
    J Mol Biol; 2009 Oct; 393(3):598-607. PubMed ID: 19683003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rigidity of the extracellular part of HER2: Evidence from engineering subdomain interfaces and shared-helix DARPin-DARPin fusions.
    Jost C; Stüber JC; Honegger A; Wu Y; Batyuk A; Plückthun A
    Protein Sci; 2017 Sep; 26(9):1796-1806. PubMed ID: 28639341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment.
    Kintzing JR; Filsinger Interrante MV; Cochran JR
    Trends Pharmacol Sci; 2016 Dec; 37(12):993-1008. PubMed ID: 27836202
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The coming of age of engineered multivalent antibodies.
    Nuñez-Prado N; Compte M; Harwood S; Álvarez-Méndez A; Lykkemark S; Sanz L; Álvarez-Vallina L
    Drug Discov Today; 2015 May; 20(5):588-94. PubMed ID: 25757598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A hot-spot motif characterizes the interface between a designed ankyrin-repeat protein and its target ligand.
    Cheung LS; Kanwar M; Ostermeier M; Konstantopoulos K
    Biophys J; 2012 Feb; 102(3):407-16. PubMed ID: 22325262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A survival selection strategy for engineering synthetic binding proteins that specifically recognize post-translationally phosphorylated proteins.
    Meksiriporn B; Ludwicki MB; Stephens EA; Jiang A; Lee HC; Waraho-Zhmayev D; Kummer L; Brandl F; Plückthun A; DeLisa MP
    Nat Commun; 2019 Apr; 10(1):1830. PubMed ID: 31015433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural determinants for improved stability of designed ankyrin repeat proteins with a redesigned C-capping module.
    Kramer MA; Wetzel SK; Plückthun A; Mittl PR; Grütter MG
    J Mol Biol; 2010 Dec; 404(3):381-91. PubMed ID: 20851127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural Basis for the Selective Inhibition of c-Jun N-Terminal Kinase 1 Determined by Rigid DARPin-DARPin Fusions.
    Wu Y; Honegger A; Batyuk A; Mittl PRE; Plückthun A
    J Mol Biol; 2018 Jul; 430(14):2128-2138. PubMed ID: 29126898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protein scaffolds: antibody alternatives for cancer diagnosis and therapy.
    Luo R; Liu H; Cheng Z
    RSC Chem Biol; 2022 Jul; 3(7):830-847. PubMed ID: 35866165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. From DARPins to LoopDARPins: novel LoopDARPin design allows the selection of low picomolar binders in a single round of ribosome display.
    Schilling J; Schöppe J; Plückthun A
    J Mol Biol; 2014 Feb; 426(3):691-721. PubMed ID: 24513107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational and biophysical robustness in a prestabilized monobody.
    Chandler PG; Tan LL; Porebski BT; Green JS; Riley BT; Broendum SS; Hoke DE; Falconer RJ; Munro TP; Buckle M; Jackson CJ; Buckle AM
    J Biol Chem; 2021; 296():100447. PubMed ID: 33617878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of next-generation protein therapeutics.
    Caravella J; Lugovskoy A
    Curr Opin Chem Biol; 2010 Aug; 14(4):520-8. PubMed ID: 20638324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody.
    Morales JF; Yu B; Perez G; Mesa KA; Alexander DL; Berman PW
    Mol Immunol; 2016 Sep; 77():14-25. PubMed ID: 27449907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beyond antibodies: using biological principles to guide the development of next-generation protein therapeutics.
    Kariolis MS; Kapur S; Cochran JR
    Curr Opin Biotechnol; 2013 Dec; 24(6):1072-7. PubMed ID: 23587963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.